Results 21 to 30 of about 25,082 (343)

Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction

BMC Cardiovascular Disorders, 2020
Background Left ventricular remodeling following ST-elevation myocardial infarction (STEMI) is associated with poor outcome, including heart failure (HF).
Damien Legallois, Clémence Macquaire, Amir Hodzic, Stéphane Allouche, Ismaïl El Khouakhi, Alain Manrique, Paul Milliez, Eric Saloux, Farzin Beygui   +8 more
doaj   +1 more source

Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study

BMC Cardiovascular Disorders, 2020
Background Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin inhibitors have shown beneficial effects in patients with heart failure.
Ik Jun Choi, Sungmin Lim, Youngdeok Hwang, Dongjae Lee, Won Jik Lee, Kwan Yong Lee, Mi-Jeong Kim, Doo Soo Jeon   +7 more
doaj   +1 more source

Synthesis and Biological Evaluation of Hydroxylated Monocarbonyl Curcumin Derivatives as Potential Inducers of Neprilysin Activity

Biomedicines, 2021
Background: Alzheimer’s disease (AD) involves impairment of Aβ clearance. Neprilysin (NEP) is the most efficient Aβ peptidase. Enhancement of the activity or expression of NEP may provide a prominent therapeutic strategy against AD.
Dimitris Matiadis, See-Ting Ng, Eric H.-L. Chen, Georgia Nigianni, Veroniki P. Vidali, Aleksander Canko, Rita P.-Y. Chen, Marina Sagnou   +7 more
doaj   +1 more source

Neprilysin, obesity and the metabolic syndrome [PDF]

International Journal of Obesity, 2010
Neprilysin (NEP), a zinc metalloendopeptidase, has a role in blood pressure control and lipid metabolism. The present study tested the hypothesis that NEP is associated with insulin resistance and features of the metabolic syndrome (MetS) in a study of 318 healthy human subjects and in murine obesity, and investigated NEP production by adipocytes in ...
Standeven, K F, Hess, K, Carter, A M, Rice, G I, Cordell, P A, Balmforth, A J, Lu, B, Scott, D J, Turner, A J, Hooper, N M, Grant, P J   +10 more
openaire   +4 more sources

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources

Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?

Neural Regeneration Research, 2022
Neurodegenerative brain disorders are a major burden in our society, such as Alzheimer´s disease. In order to repair or prevent such diseases, drugs are designed which enter the brain, but the blood-brain barrier limits their entry and the search for ...
Christian Humpel
doaj   +1 more source

Neprilysin as a Biomarker: Challenges and Opportunities

Cardiac Failure Review, 2020
Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care.
Pavo, Noemi, Prausmüller, Suriya, Bartko, Philipp E, Goliasch, Georg, Hülsmann, Martin   +4 more
openaire   +5 more sources

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]

, 2016
BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C., Baxter, A., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., Dayanandan, R., Emberson, J., Haynes, R., Herrington, W.G., Hill, M., Judge, P.K., Kalra, P.A., Knott, C., Landray, M.J., McMurray, John J., Murphy, K., Roderick, P., Staplin, N., Storey, B.C., Taal, M., Tomson, C., Wheatley, K., Wheeler, D.C.   +23 more
core   +4 more sources

Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Neprilysin is a metalloprotease involved in proteolysis of numerous peptides, including natriuretic peptides, and is of prognostic and therapeutic importance in heart failure with reduced ejection fraction.
Yogesh N. V. Reddy, Seethalakshmi R. Iyer, Christopher G. Scott, Richard J. Rodeheffer, Kent Bailey, Gregory Jenkins, Anthony Batzler, Margaret M. Redfield, John C. Burnett, Naveen L. Pereira   +9 more
doaj   +1 more source

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure

Медицинский совет, 2020
The article describes the possibility of using a new class of angiotensin II/neprilysin receptor inhibitor - sacubitrile/valsartan for the treatment of chronic heart failure (CHF). The role of the natriuretic peptide system in the pathogenesis of CHF and
V. S. Nikiforov
doaj   +1 more source